These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11142756)

  • 41. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model.
    Kaback MM
    Eur J Pediatr; 2000 Dec; 159 Suppl 3():S192-5. PubMed ID: 11216898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The incidence and carrier frequency of Tay-Sachs disease in the French-Canadian population of Quebec based on retrospective data from 24 years, 1992-2015.
    Sillon G; Allard P; Drury S; Rivière JB; De Bie I
    J Genet Couns; 2020 Dec; 29(6):1173-1185. PubMed ID: 32302469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening for Tay-Sachs disease: a note of caution.
    Rosner F
    J Clin Ethics; 1991; 2(4):251-2. PubMed ID: 1804394
    [No Abstract]   [Full Text] [Related]  

  • 44. Tay-Sachs disease and HEXA mutations among Moroccan Jews.
    Kaufman M; Grinshpun-Cohen J; Karpati M; Peleg L; Goldman B; Akstein E; Adam A; Navon R
    Hum Mutat; 1997; 10(4):295-300. PubMed ID: 9338583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students.
    Barlow-Stewart K; Burnett L; Proos A; Howell V; Huq F; Lazarus R; Aizenberg H
    J Med Genet; 2003 Apr; 40(4):e45. PubMed ID: 12676918
    [No Abstract]   [Full Text] [Related]  

  • 46. Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort.
    Cecchi AC; Vengoechea ES; Kaseniit KE; Hardy MW; Kiger LA; Mehta N; Haque IS; Moyer K; Page PZ; Muzzey D; Grinzaid KA
    Mol Genet Genomic Med; 2019 Aug; 7(8):e836. PubMed ID: 31293106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population-based carrier screening and prenatal diagnosis.
    Strom CM
    MLO Med Lab Obs; 2004 Aug; 36(8):12-7; quiz 20-1. PubMed ID: 15366363
    [No Abstract]   [Full Text] [Related]  

  • 48. Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers.
    Peleg L; Frisch A; Goldman B; Karpaty M; Narinsky R; Bronstein S; Frydman M
    Eur J Hum Genet; 1998; 6(2):185-6. PubMed ID: 9781065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of the physician in screening for carriers of Tay-Sachs disease.
    Lowden JA
    Can Med Assoc J; 1978 Sep; 119(6):575-8. PubMed ID: 709448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterozygosity for Tay-Sachs and Sandhoff diseases among Massachusetts residents with French Canadian background.
    Prence EM; Jerome CA; Triggs-Raine BL; Natowicz MR
    J Med Screen; 1997; 4(3):133-6. PubMed ID: 9368869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening for the Tay-Sachs carrier: a compromise program.
    Potter JL; Robinson HB
    Clin Chem; 1981 Apr; 27(4):523-5. PubMed ID: 7471417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterozygosity for Tay-Sachs and Sandhoff diseases in non-Jewish Americans with ancestry from Ireland, Great Britain, or Italy.
    Branda KJ; Tomczak J; Natowicz MR
    Genet Test; 2004; 8(2):174-80. PubMed ID: 15345116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pedigree discriminant analysis of two French Canadian Tay-Sachs families.
    Keats BJ; Elston RC; Andermann E
    Genet Epidemiol; 1987; 4(2):77-85. PubMed ID: 2953646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pitfalls in Tay-Sachs carrier detection: physician referral patterns and patient ignorance.
    Shapiro DA; Shapiro LR
    N Y State J Med; 1989 Jun; 89(6):317-9. PubMed ID: 2739956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The molecular basis of Tay-Sachs disease: mutation identification and diagnosis.
    Mahuran DJ; Triggs-Raine BL; Feigenbaum AJ; Gravel RA
    Clin Biochem; 1990 Oct; 23(5):409-15. PubMed ID: 2147596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease.
    Ekstein J; Katzenstein H
    Adv Genet; 2001; 44():297-310. PubMed ID: 11596991
    [No Abstract]   [Full Text] [Related]  

  • 57. Genetic Carrier Screening in the Twenty-first Century.
    Yao R; Goetzinger KR
    Clin Lab Med; 2016 Jun; 36(2):277-88. PubMed ID: 27235912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tay-Sachs disease in an Arab family due to c.78G>A HEXA nonsense mutation encoding a p.W26X early truncation enzyme peptide.
    Haghighi A; Masri A; Kornreich R; Desnick RJ
    Mol Genet Metab; 2011 Dec; 104(4):700-2. PubMed ID: 21967858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tay-Sachs disease: Part 2. Model of a fatal, preventable, metabolic, genetic disorder.
    Hecht F; Anatole P; Szucs SC
    Ariz Med; 1984 Oct; 41(10):661-5. PubMed ID: 6508567
    [No Abstract]   [Full Text] [Related]  

  • 60. The Tay-Sachs disease prevention program in Australia: Sydney pilot study.
    Burnett L; Proos AL; Chesher D; Howell VM; Longo L; Tedeschi V; Yang VA; Siafakas N; Turner G
    Med J Aust; 1995 Sep; 163(6):298-300. PubMed ID: 7565235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.